Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
An artificial intelligence-guided workflow for initial evaluation of left ventricular ejection fraction in echocardiography is non-inferior to initial assessment by a sonographer, according to findings from a blinded, randomized, non-inferiority clinical trial.
A bidirectional relationship exists between atrial fibrillation (AF) and myocardial infarction (MI) as a result of shared risk factors and both direct and indirect mechanisms. In this Review, Frederiksen and colleagues discuss the pathogenesis, prevention and management of AF in patients with MI and of MI in patients with AF.
In this Review, the authors discuss current treatment regimens for lowering plasma LDL cholesterol levels to reduce the risk of cardiovascular disease, highlight treatment gaps and challenges, as well as describe opportunities raised by novel available therapies and potential future therapeutic approaches.
Research consistently shows that gender-affirming practices improve markers of cardiovascular health. Consequently, the focus of the management of the cardiovascular health of transgender and non-binary populations should not be on their hormone therapies and surgical histories, but should instead be rooted in the routine screening of cardiovascular risk factors.
Desmosomal protein degradation that occurs via a mechanism involving the ubiquitin–proteasome system might underlie the development of arrhythmogenic cardiomyopathy.
Factor XIa inhibitors are being tested in clinical trials, with the assumption that these agents are as effective as direct oral anticoagulants but cause fewer bleeding events. Findings from phase II trials of direct inhibitors of factor XIa for the prevention of first-ever and recurrent ischaemic stroke or recurrent major coronary artery events suggest fewer bleeding events but with uncertainty about efficacy.
In this Review, Gawaz and colleagues discuss the pathophysiological role of platelets in acute myocardial ischaemia, vascular inflammation and atherosclerotic progression, summarize the current clinical concepts in antiplatelet therapy and describe novel therapeutic targets for antiplatelet drugs that are currently in development.
Establishing and enforcing LGBTQ-inclusive policies at the national, state and institutional level are essential for advancing health equity and ensuring the highest quality cardiology workforce.
Glucagon-like peptide 1 (GLP1) receptor agonists reduce the rate of major adverse cardiovascular events in people with type 2 diabetes mellitus. In this Review, Ussher and Drucker discuss the possible mechanisms of cardiovascular benefit of GLP1 receptor agonists and highlight the novel GLP1-based multi-agonists currently in development.
In the CLEAR Outcomes trial, bempedoic acid lowered plasma LDL-cholesterol levels and reduced the incidence of major adverse cardiovascular events in individuals who were intolerant to statin therapy.
Tricuspid transcatheter edge-to-edge repair in patients with severe tricuspid regurgitation improved quality of life and reduced disease severity compared with medical therapy
A wrist-worn, transdermal sensor can be used to measure plasma levels of cardiac troponin I, potentially facilitating the diagnosis of myocardial infarction.
In patients with complex coronary lesions, percutaneous coronary intervention guided by intravascular imaging improved cardiovascular outcomes compared with percutaneous coronary intervention guided by angiography.
MK-0616, an oral inhibitor of PCSK9, safely and effectively lowers plasma levels of LDL cholesterol in a dose-dependent manner in patients with hypercholesterolaemia.
Immediate complete revascularization is as safe and effective as staged complete revascularization in patients with acute coronary syndrome and multivessel disease, according to findings from the BIOVASC trial.
In the Evolut Low Risk study, transcatheter aortic valve implantation in low-risk patients with severe aortic stenosis compared favourably with surgical aortic valve replacement in terms of all-cause mortality or disabling stroke at 3 years.
According to findings from the PULSED AF trial, pulsed field ablation for atrial fibrillation is associated with a very low incidence of serious procedure-related adverse events and has an effectiveness consistent with that of established thermal ablation methods.
Findings from the STELLAR trial show that the addition of sotatercept to background therapy in patients with pulmonary arterial hypertension significantly improved exercise capacity compared with placebo.
Deisseroth and colleagues used a novel optogenetic system to pace the heart and determine whether an increase in heart rate can evoke anxiety-like behaviours.
In this Review, Lucia and colleagues explain why obesity is an evolutionarily novel condition, summarize the epidemiological evidence for its detrimental cardiometabolic consequences, discuss the major mechanisms involved in the association between obesity and the risk of cardiometabolic diseases, and examine the evidence for potential ‘healthy’ phenotypes associated with obesity.
